1.Challenges of non-communicable-diseases and control policies in China
Chinese Journal of Hospital Administration 2013;29(7):534-537
Non-communicable-diseases(NCDs)have become leading death causes and major health challenges for the Chinese people,incurring direct and indirect economic burden of diseases on families and the society,and even posing a serious threat to social-economic development sustainability of the country.Given their complex causes,NCDs mostly result from unhealthy lifestyle of the individuals,along with complex multiple social determinants.Evidences from home and abroad prove NCDs as preventable and controllable,which call for powerful government policy commitments and leadership.The government should make health policies part of social policies,build such intervention platform as Healthy City,rebuild the health service system,promote universal coverage of cost-effective interventions,and involve the entire society,reinforce general measures such as planning and performance monitoring.All of which can achieve desired outcomes for NCD control in the end.
2.Surveys into the medical needs of outpatients
Yuantai DU ; Chunqi LIANG ; Jiabin LIN
Chinese Journal of Hospital Administration 1996;0(10):-
Objective To improve outpatient medical care. Methods A sample survey was conducted into 1716 outpatients during 6 days in October of 2004 using questionnaires that covered such items as the patients' choice of hospitals, their choice of doctors, their medical needs and their needs for continuous services. Results The medical needs of the patients, regardless of gender, age, and form of payment (personal payment, medical insurance or treatment at public expenses), are, in terms of urgency, disease relief, safety, respect, service, and the right to be informed. Ranking first in the needs for continuous medical services is medical appointments, with telephone follow-ups coming next. Conclusion Outpatients have diversified medical needs and hospitals ought to attach importance to relieving patients from disease, ensuring medical safety, respecting patients, improving services, bettering continuous medical services, and satisfying the needs of patients at different levels.
3.The effect of Aescin on chronic venous insufficiency:a randomized controlled multi-center clinical trial
Guoxiang DONG ; Zhonggao WANG ; Faqi LIANG ; Chunqi ZHAO ; Zhuming JIANG
Chinese Journal of General Surgery 1997;0(04):-
0.05). Body weight, blood pressure, blood routine test and blood biochemical parameters did not change in the two groups. Only mild side reactions of aescin was found and there was no dropout in the study group, whereas 7 patients dropped out in the control group due to the intolerance for the pressure. Conclusion Aescin has similar efficacy and fewer side effects compared with the compression stocking method in the treatment of chronic venous insufficiency.
4.Study on the application of zebrafish model in the early stage of renal toxicity in drug development
Jinfeng LIANG ; Yong ZHU ; Hongyao ZHANG ; Qiaocong LAO ; Minkang MA ; Chunqi LI
Chinese Journal of Comparative Medicine 2016;26(9):30-35
Objective To evaluate the renal toxicity of vancomycin hydrochloride and irbesartan tablets using the zebrafish model. Methods After construction of AB zebrafish kidney model, the fish were treated with drug after fertilization 2 days (2 dpf) to 5 dpf. At the end of the experiment, the number of renal edema zebrafish was counted in each experimental group to evaluate the renal toxicity of drugs. Results The zebrafish development was normal and no obvious toxicity at the dose of 16?4 ng/fish (1/10 MNLD) for vancomycin, and zebrafish renal edema occurred rate was 3?3%, 10% and 10% respectively at the dose of 54?7 ng/fish (1/3 MNLD), 164 ng/fish (MNLD) and 273 ng/fish ( LD10 ) with the death rate of 0%, 0% and 16?7%, respectively, which indicated that there was significant renal toxicity of vancomycin at the dose of 54?7 ng/fish (1/3MNLD) to 273 ng/fish (LD10). Irbesartan didn’t induce renal toxicity at the dose of 8?3 μg/mL (1/10 MNLC) to 91 μg/mL (LC10). Conclusions The zebrafish model of renal toxicity can be used for the early evaluation of drug renal toxicity and we made evaluation of the renal toxicity of vancomycin and irbesartan with this model.